Search

Alzheimer's disease (AD) is the most common neurodegenerative disease in older age. Pathophysiological changes begin in the brains of affected individuals many years before any clinical signs are observed. Although brain imaging and neurophysiological analyzes are useful to reveal anatomical and functional changes in patients whose diagnosis of AD is considered based on clinical examination, their contribution to the diagnosis is quite limited, particularly in the early stages of the disease. Some biological markers are important as laboratory support in the early diagnosis of AD. Biomarkers are objectively measurable and evaluable indicators that serve to identify normal biological processes, pathological processes, and therapeutic response rates. Biomarkers have the potential to predict the likelihood of disease, assist in early diagnosis, and contribute to monitoring treatment effectiveness. This article aimed to provide information about the use of proximity extension assay technology in biomarker studies in AD. [ABSTRACT FROM AUTHOR]